{"url_path":"/sec/orka/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-055769-index.html","accession_number":"0001213900-26-055769","cik":"0000907654","ticker":"ORKA","issuer_name":"Oruka Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-055769-index.html","primary_entity_key":"0000907654","primary_entity_name":"Oruka Therapeutics, Inc."},"word_count":419,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n☒ **QUARTERLY REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐ **TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES ACT OF 1934**\n\n \n\n**For the transition period from ________ to ________**\n\n \n\n**Commission file number: 000-22873**\n\n \n\n**Oruka Therapeutics, Inc.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n**Delaware**   **36-3855489**\n\n(State or other jurisdiction of\n\nincorporation or organization)   (I.R.S. Employer\n\nIdentification No.)\n\n \n\n**855 Oak Grove Avenue**    \n\n**Suite 100**    \n\n**Menlo Park, California**   **94025**\n\n(Address of principal executive offices)   (Zip Code)\n\n \n\n(650) 606-7910\n\n(Registrant’s telephone number, including\narea code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class   Trading Symbol(s)   Name of each exchange on which registered\n\nCommon stock, par value $0.001 per share   ORKA   The Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days.\n\n \n\nYes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding\n12 months (or for such shorter period that the registrant was required to submit such files).\n\n \n\nYes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act:\n\n \n\nLarge accelerated filer ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒ Smaller reporting company ☒\n\n    Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs of April 30, 2026, there were 60,312,101 shares of the registrant’s\ncommon stock outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Table of Contents**\n\n \n\n \n \n**Page**\n\n \n[PART I. Financial Information](#a_001)"}